Kan Huang, Zilun Li, Xi He, Jun Dai, Bingding Huang, Yongxia Shi, Dongxiao Fan, Zefeng Zhang, Yunchong Liu, Na Li, Zhongyu Zhang, Jiangyun Peng, Chenshu Liu, Renli Zeng, Zhipeng Cen, Tengyao Wang, Wenchao Yang, Meifeng Cen, Jingyu Li, Shuai Yuan, Lu Zhang, Dandan Hu, Shuxiang Huang, Pin Chen, Peilong Lai, Liyan Lin, Jielu Wen, Zhengde Zhao, Xiuyi Huang, Lining Yuan, Lifang Zhou, Haoliang Wu, Lihua Huang, Kai Feng, Jian Wang, Baolin Liao, Weiping Cai, Xilong Deng, Yueping Li, Jianping Li, Zhongwei Hu, Li Yang, Jiaojiao Li, Youguang Zhuo, Fuchun Zhang, Lin Lin, Yifeng Luo, Wei Zhang, Qianlin Ni, Xiqiang Hong, Guangqi Chang, Yang Zhang, Dongxian Guan, Weikang Cai, Yutong Lu, Fang Li, Li Yan, Meng Ren, Linghua Li, Sifan Chen
Thrombosis represents the leading cause of death and disability upon major adverse cardiovascular events (MACEs). Numerous pathological conditions such as COVID-19 and metabolic disorders can lead to a heightened thrombotic risk; however, the underlying mechanisms remain poorly understood. Our study illustrates that 2-methylbutyrylcarnitine (2MBC), a branched-chain acylcarnitine, is accumulated in patients with COVID-19 and in patients with MACEs. 2MBC enhances platelet hyperreactivity and thrombus formation in mice...
February 20, 2024: Cell Metabolism